Craig H. Moskowitz

Craig H. Moskowitz, MD is Division Chief of Hematology and Professor of Medicine at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He is one of the most prominent clinical investigators in Hodgkin lymphoma (HL) globally, known for leading the ECHELON-1 trial — a phase III randomized study published in NEJM (2018) comparing brentuximab vedotin plus AVD (A+AVD) with standard ABVD chemotherapy in previously untreated advanced classical Hodgkin lymphoma. ECHELON-1 demonstrated that A+AVD significantly improved modified progression-free survival compared with ABVD, leading to FDA and EMA approval of A+AVD as a preferred frontline regimen for advanced HL and representing the first phase III improvement over ABVD in over three decades. Prior to ECHELON-1, Dr. Moskowitz made foundational contributions to salvage chemotherapy strategies in relapsed/refractory HL, including the development and validation of ICE (ifosfamide, carboplatin, etoposide) chemotherapy and the application of PET-adapted therapy to guide transplant eligibility decisions. He has also been a leading investigator in clinical trials of pembrolizumab in relapsed/refractory classical HL (KEYNOTE-204) and in the design of novel transplant consolidation strategies. Dr. Moskowitz formerly directed the Lymphoma Service at MSK for many years before joining Sylvester.